Viridian Therapeutics, Inc.
VRDNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeViridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company carries a $1.75B market cap, placing it firmly in the small-cap category. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
Market Cap
$1.75B
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
-6.32
EPS (TTM)
$-3.35
EPS (Fwd)
$-2.51
ROE
-58.1%
ROA
-33.3%
Cash
$762.2M
Total Debt
$53.4M
Free CF
-$182.6M
52W Change
12.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $762.2M in cash comfortably exceeding the $53.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$182.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -58.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $1.8M to $70.8M.
With cash comfortably exceeding debt, VRDN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing VRDN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.